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In a recent issue of Critical Care, Poole and colleagues
found that plasma citrulline concentration and
glucose absorption were reduced in 20 critically ill
patients compared with 15 controls; however, the
authors found no correlation between these two
variables. This study highlights the question of the
accuracy of plasma citrulline for assessing small bowel
function in critically ill patients. Future studies should
take into account the type of intestinal failure
considered, the particular metabolism of citrulline, the
time of plasma citrulline measurement, as well as the
range of citrullinemia considered.the authors, however, the study was possibly underpoweredIn a recent issue of Critical Care, Poole and colleagues [1]
evaluated the link between plasma citrulline concentration
and glucose absorption in critically ill patients. This is an
important contribution to the study of acute intestinal
failure in the ICU.
Evaluating small bowel function and integrity is
challenging in the critically ill [2]. Small bowel damage
might be central in the development of systemic inflam-
matory response syndrome, bacterial translocation, and
multiple organ failure [3]. In addition, small bowel damage
might make it difficult or impossible to use the enteral
route for feeding or medication intake. Citrulline is an
amino acid not incorporated into proteins that is mainly
synthesized by small bowel enterocytes [4]. Fifteen years
ago, Crenn and colleagues [5,6] demonstrated that plasma
citrulline concentration was a precise biomarker of small
bowel function in patients with short bowel syndrome and
villous atrophy-associated small bowel diseases, reflecting* Correspondence: gpiton@chu-besancon.fr
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unless otherwise stated.small bowel length and villi size, respectively. To date,
numerous studies have confirmed these results in
non-critically ill patients.
The question is to know whether plasma citrulline is
also a valid biomarker in critically ill patients [7]. The
paper of Poole and colleagues [1] is therefore welcomed.
They confirmed that plasma citrulline concentration and
glucose absorption were lower in 20 critically ill patients
compared with 15 controls. Despite a trend toward a
positive correlation (R = 0.28, P = 0.12), the link between
plasma citrulline concentration and glucose absorption
was not statistically significant. The authors concluded
that plasma citrulline concentration was not a biomarker
of glucose absorption in critically ill patients. As noted by
to explore the link between plasma citrulline concentration
and glucose absorption.
All in all, this apparently disappointing study highlights
the need to clarify the interest and limits of plasma citrulline
concentration in the critically ill. On the one hand, it is
reasonable to assume that plasma citrulline concentration is
related to small bowel function in the critically ill. First, the
plasma citrulline concentration is low in more than half of
critically ill patients [1,8,9]. Second, low plasma citrulline
concentrations are associated with a poor prognosis
[8,9]. Third, plasma citrulline and C-reactive protein
concentrations are inversely correlated [8-10], and low
plasma citrulline is associated with bacterial translocation
[10,11]. Fourth, low plasma citrulline concentrations were
found to be associated with elevated intestinal fatty acid
binding protein concentration, a specific biomarker of
enterocyte damage [11,12]. Fifth, plasma citrulline concen-
tration was found to be lower among critically ill patients
presenting with signs of intestinal dysfunction, such as
feeding intolerance, ileus, diarrhea, or gastrointestinal
bleeding [13]. On the other hand, plasma citrulline
concentration might lack accuracy among critically ill
patients. First, the metabolism of citrulline is complex. It
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arginine, on the level of systemic inflammation because
nitric oxide synthase transforms arginine into nitric oxide
plus citrulline, and on arginine bioavailability because
citrulline might be overmetabolized as a source of arginine
[4,14]. Second, the time of plasma citrulline measurement
might be crucial. Indeed, plasma citrulline concentration
describes a U-curve during ICU stay [8]. Even if plasma
citrulline concentration is often low at the time of ICU
admission, it is even lower 1 or 2 days later, whereas it
tends to increase in survivors after 1 week. Because of this
intra-individual variability, the time of measurement
should be taken into account. Third, the present study
suggests that plasma citrulline does not reflect correctly
the absorptive function in the critically ill. Only few and
preliminary studies have evaluated the links between
plasma citrulline concentration, absorptive function, and
barrier function in the ICU. Fourth, the range of normality
for plasma citrulline concentration, which is between 20
and 40 μmol.L−1 in the stable patient, might not be
adapted in the critically ill. Whereas a very low plasma
citrulline concentration, ≤10 μmol.L−1, is likely to indicate
an altered small bowel function, a plasma citrulline
concentration between 10 and 20 μmol.L−1 might be
in a grey zone for the interpretation [15].
In conclusion, we need additional data in this field.
Due to its metabolism and particular kinetics in the
critically ill, plasma citrulline concentration might not
be as accurate as in stable patients for determining small
bowel function. On the other hand, plasma citrulline is
probably an indicator of small bowel function that should
be integrated into a clinical context.Competing interests
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